Takeda Pharmaceutical is increasing its pipeline for uncommon illness medication, reaching an settlement for world rights to a drug from Protagonist Therapeutics that’s in late-stage growth for the remedy of the uncommon blood illness polycythemia vera. Below deal phrases introduced Thursday, Takeda can pay $300 million upfront to share within the growth of the drug Rusfertide. Newark, California-based Protagonist stays […]
